Sign In

David S. Brooks

Digital Health | Life Sciences | Diagnostics | Product & Strategy | Business Leader | Entrepreneur

David S. Brooks is a professional with a significant background in the healthcare and technology sectors, currently serving as Co-Founder at Casandra.AI. His LinkedIn profile indicates that he is based in Mooresville, North Carolina, and has amassed a substantial network of over 6,000 followers and 500+ connections.

In addition to his role at Casandra.AI, Brooks has experience in various leadership positions, including his tenure at NeoGenomics Laboratories. His expertise encompasses areas such as healthcare technology and innovation, reflecting a commitment to advancing the capabilities of medical services through artificial intelligence and data solutions.

Brooks's professional journey highlights his focus on leveraging technology to improve healthcare outcomes, making him a notable figure in the intersection of these fields.1

Highlights

Aug 31 · linkedin

Having spent countless hours working through the FDA's List of Cleared or Approved Companion Diagnostic Devices in developing https://cdxtests.com, Casandra.AI created the attached list to help visualize approved companion diagnostics (CDx) in a way that I believe is easier to understand, particularly within a clinical context.

This information reflects a few important points:

  1. A CDx should more accurately be viewed as the combination of Indication-Biomarker-Biomarker Details-Drug/Therapy than an actual assay/panel. In the early days, in a 1 test:1 drug model, that made more sense. Today, particular with comprehensive genetic profiles (CGP) (Foundation Medicine's FoundationOne CDx, TSO500, Guardant Health's Guardant360 CDx, and Tempus AI's xT CDx), a "CDx Test" can address more than 1 Indication-Biomarker-Drug instance. For example, FoundationOne CDx currently addresses 54% of all instances shown on the "Know Your Companions" list. [Note: technically these should also incorporate specimen type, but I feel that introduces an unnecessary level of complexity when trying to summarize this data.]

  2. This table attempts to capture the additional dimension added by tissue-agnostic therapies with a 'Solid Tumor' indication. As a result, the total count of Indication-Biomarker-Drug instances only counts solid tumor indications with existing approvals (24 solid tumor cancer types). As a result, this underestimates the potential "reach" of tissue-agnostic therapies as well as their associated CDx.

  3. This data is current as of the FDA's 05/01/2024 release. They recently updated the list on 08/21/2024, which only removed two approvals related to Exkivity which has been voluntarily removed from the market (it is shown in bold red on the attached list).

  4. Through 08/21/204, there has only been a single new approval in 2024 - Labcorp's AAVrh74 antibody assay (nAbCyte Assay) for BEQVEZ. However, less than a week after the FDA's most recent update, the FDA approved Illumina's TruSight Oncology (TSO500) for 2 CDx (one 'Solid Tumor' [NTRK 1/2/3 fusions] and the other potentially a 'Solid Tumor' [RET fusions] but limited to NSCLC for the time being). This will undoubtedly shake up competition in the CGP segment as this is the first approved CGP by an IVD.

For a complete break-down of the companion diagnostic market, check out https://lnkd.in/exDCJ6_n

#WorldCDx kicks off this week in Boston! Should be an exciting event with lots to talk about.

#WorldCBandCDxBoston, #CDx, #diagnostics, #precisionmedicine

Aug 30 · linkedin

Exciting News!

Casandra.AI has just launched CDxTests.com — the most comprehensive directory of FDA-approved companion diagnostics, searchable by both indication and therapy.

Our mission is clear: every doctor should have the power to order the most precise diagnostic test for their patients, seamlessly integrated into any EHR, from any lab, anywhere. No barriers, just better care.

Related Questions

What is Casandra.AI's main focus or product?
How did David S. Brooks transition from Tenex Capital Management to Casandra.AI?
What are some of the key achievements of David S. Brooks at Baker Hughes?
How does David S. Brooks' experience in organizational transformation benefit Casandra.AI?
What inspired David S. Brooks to co-found Casandra.AI?
David S. Brooks
David S. Brooks, photo 1
David S. Brooks, photo 2
Add to my network

Location

Mooresville, North Carolina, United States